4D Molecular Therapeutics Inc (FDMT) — Cash Flow Reinvestment Rate

Latest as of December 2025: 4.54x

4D Molecular Therapeutics Inc (FDMT) has a Cash Flow Reinvestment Rate of 4.54x as of December 2025, reinvesting $129.55 Million (capex $631.00K plus investments $-128.92 Million) from operating cash flow of $28.55 Million. Check 4D Molecular Therapeutics Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

4.54x

(Capex + Investments) / Operating CF

Total Reinvested

$129.55 Million

Capex + Investments

Operating Cash Flow

$28.55 Million

USD

Capital Expenditures

$631.00K

USD

4D Molecular Therapeutics Inc Cash Flow Reinvestment Rate (2017–2017)

Historical reinvestment intensity for 4D Molecular Therapeutics Inc across 1 annual periods. Explore 4D Molecular Therapeutics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for 4D Molecular Therapeutics Inc (2017–2017)

Year-by-year capital reinvestment analysis for 4D Molecular Therapeutics Inc. For live market cap and broader valuation context, see how much is 4D Molecular Therapeutics Inc worth.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2017	1.07x	$8.80 Million	$8.24 Million	$573.00K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow